Middle East Pharmaceutical Industries Co. announces its Interim Financial results for the Period Ending on 2025-09-30 ( Nine Months )
| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 107.95 | 81.06 | 33.172 | 117.66 | -8.252 |
| Gross Profit (Loss) | 62.47 | 45.7 | 36.695 | 73.63 | -15.156 |
| Operational Profit (Loss) | 11.01 | 6.94 | 58.645 | 28.26 | -61.04 |
| Net profit (Loss) | 8.28 | 3.87 | 113.953 | 24.81 | -66.626 |
| Total Comprehensive Income | 8.16 | 4.04 | 101.98 | 22.57 | -63.845 |
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Sales/Revenue | 322.97 | 258.01 | 25.177 |
| Gross Profit (Loss) | 196.37 | 154.28 | 27.281 |
| Operational Profit (Loss) | 61.58 | 43.79 | 40.625 |
| Net profit (Loss) | 52.49 | 35.04 | 49.8 |
| Total Comprehensive Income | 50.12 | 34.79 | 44.064 |
| Total Shareholders Equity (after Deducting Minority Equity) | 371.33 | 326.19 | 13.838 |
| Profit (Loss) per Share | 2.62 | 1.75 | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is | The key value drivers of the business continue to see robust growth year on year, with revenues growing by 33%, reaching SAR 107.95m in Q3 of this year as compared to the same quarter of last year. This was primarily driven by significant increases in Private and Export sector’s sales, which grew 61% and 11% respectively, whilst Public sector sales remained flat. |
| The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is | Net profit increased by 114%, equivalent to SAR 4.41m mainly due to a 37% increase in gross profit (SAR 16.77m) due to the growth in volumes sold with improved gross margin. This is partially offset by an increase in selling & distribution expenses; and general & administrative expenses, highlighting the company’s continuing commitment to invest in the long-term sustainable growth. |
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is | The decrease of 8% or SAR 9.71m in revenue during the current quarter (SAR 107.95m), as compared to the previous quarter of the year (SAR 117.66m) was mainly attributed to the seasonality dependent demand of the products wherein the Private sector customers mostly tend to purchase goods in the second quarter ahead of the summer vacation and Hajj holidays. This was partially offset by the 14.3% increase in Public sector sales due to an increase in product deliveries during the current quarter compared to the previous quarter under one of the government tenders awarded to the company. |
| The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is | The decrease in the Company’s net profit for the current quarter by 67% (SAR 16.53m) as compared with the previous quarter of the year was due to the lower revenue generated in the current quarter and the change in channel sales mix particularly from a higher contribution percentage of Public sector sales leading to the decline in the gross margin. |
| The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is | The Company witnessed a 25% increase in revenues Year-on-Year, reaching SAR 322.97m for the period. This was driven by 26% increase in Private sector sales, 34% increase in Public sector sales, and a 7% increase in Export sector sales, which reached SAR 211.95m, SAR 76.22m and SAR 34.80m, respectively.
In addition, revenues in key therapeutic areas, particularly in pain management (+94%), cardiometabolic (+65%), respiratory (+26%) and dermatology (+20%) have contributed to the overall growth in the top line revenue. |
| The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is | Net Profit for the period has increased by 50% Year-on-Year, reaching SAR52.49m for the period, as a result of 25% increase in revenue with improved gross margins across all distribution channels. This is partially offset by an increase in selling & distribution expenses; and in general & administrative expenses, highlighting the company’s continuing commitment to invest in the long-term sustainable growth. Notwithstanding, the company’s operating expenses to revenue ratio was lower compared to the same period of last year, which has resulted in a higher operating profit by 41%. |
| Statement of the type of external auditor's report | Unmodified conclusion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | The consolidated financial statements of the Group for the year ended 31 December 2024 were audited by another auditor who expressed an unmodified opinion on those consolidated financial statements on 25 Ramadhan 1446H (corresponding to 25 March 2025). Further, the interim condensed consolidated financial statements of the Group for the three-month and nine-month periods ended 30 September 2024 and three-month period ended 31 March 2025 were reviewed by another auditor who expressed an unmodified review conclusion on those interim condensed consolidated financial statements on 8 Jumada al-Ula1446H (corresponding to 10 November 2024) and 16 Dhul Qa’dah 1446 (corresponding to 14 May 2025), respectively. |
| Reclassification of Comparison Items | Certain comparative figures have been reclassified to conform with the classification used for the period ending 30 September 2025. |
| Additional Information | None |
| Attached Documents |  |
Comments